Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 17, 2018
ADMA Biologics Receives PDUFA Date for RI-002
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
October 17, 2018
BrainsWay to Showcase Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at the 2018 Annual Psych Congress
HACKENSACK, N.J., Oct. 17, 2018 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BRIN.TA), the parent company of BrainsWay USA, Inc., and a global leader in the advanced ...
October 17, 2018
STRATA Skin Sciences to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
HORSHAM, Pa., Oct. 17, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, ...
October 17, 2018
OncoCyte Corporation to Present at the BIO CEO Investor Forum
ALAMEDA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today ...
October 17, 2018
Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
October 17, 2018
Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome
BOSTON, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
October 17, 2018
Albireo Receives FDA Fast Track Designation for A4250
BOSTON, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
October 17, 2018
BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
NEW YORK and PETACH TIKVAH, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies ...
October 17, 2018
Bionano and Genoox Launch Integrated Platform for Identification of Structural Variants in DNA
SAN DIEGO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ...
October 17, 2018
First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, today announced that the first patient of a Phase 1/2 clinical trial ...
October 16, 2018
Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA
LAVAL, QC , Oct. 16, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic" or the "Corporation") announced today that it has completed a Type C ...
October 16, 2018
Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018
IRVING, Texas, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s progress in ...
October 16, 2018
Neovasc Announces Publication of a Peer-Reviewed Article on Tiara™ Cases in Circulation: Cardiovascular Interventions
VANCOUVER , Oct. 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral ...
October 16, 2018
Checkpoint Therapeutics Appoints Christian Béchon to its Board of Directors
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
October 16, 2018
Athenex to Present Positive Data of Oraxol Clinical Trial in Breast Cancer at the ESMO 2018 Congress
BUFFALO, N.Y., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
October 16, 2018
Zosano Appoints New Chief Financial Officer
FREMONT, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver ...
October 16, 2018
Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi ...
October 16, 2018
Bionano Genomics’ Structural Variation Results Presented at ASHG 2018 Provide Insights in Cancer and Genetic Disease
SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ...
October 16, 2018
Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
PALO ALTO, Calif., Oct. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced ...
October 16, 2018
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
PALO ALTO, Calif., Oct. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced ...
Page 32 of 138